KARD · Kardigan, Inc. · Investor Relations

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 30, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee.

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 2, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, will

Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027 Strong cash

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 22, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 17, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN

New Phase 2 data on tonlamarsen in patients with uncontrolled hypertension to be presented in late-breaking session on Saturday, March 28 Prolaio to present LINK-HF2 research highlighting the role of continuous monitoring and novel biomarkers in advancing cardiovascular therapeutics and care

Andy Pasternak appointed chief strategy officer, bringing extensive leadership in biopharmaceutical business development and company growth Clinical data readouts expected in 2026 across all three late-stage programs, marking a significant step forward in addressing unmet cardiovascular needs in

Results presented in oral session demonstrated that treatment with ataciguat reduced aortic valve calcium and improved cardiac function and output compared to placebo SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., November 7, 2025 — Kardigan, a heart health company modernizing cardiovascular

Financing will drive continued progress of three late-stage programs in specific types of dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis where no treatments exist New capital reinforces Kardigan’s path to multiple data readouts beginning in 2026 SOUTH SAN

Data simultaneously published in The Journal of the American College of Cardiology (JACC) Results presented in late-breaking oral session showed danicamtiv was well tolerated with significant improvements in ventricular and atrial function in patients with genetic dilated cardiomyopathy (DCM) Data